Posted on: June 13, 2022
BCCDC guidance documents updated include Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19, Practice Tool #1 – Assessment Guide for Clinicians, Clinical Practice Guide for the Use of Tixagevimab/Cilgavimab (EvusheldTM) and COVID-19 Vaccine (Ad26.COV2.S [recombinant]) Janssen COVID-19 Vaccine.